Search

VB2-011

This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG). … According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

EW-A-401

EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.

Praconase

Hydracarbazine

Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

Brigatinib

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

MDX-1303

MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

Alicaforsen

Torcetrapib

Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

Annamycin